3978 Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices 

207, subpart D; in these proceedings, 

entries of appearance will be considered 

timely if filed no later than 14 days after 

publication of this notice in the Federal 

Register. The Secretary will prepare a 

public service list containing the names 

and addresses of all persons, or their 

representatives, who are parties to these 

reviews upon the expiration of the 

period for filing entries of appearance. 

Limited disclosure of business 

proprietary information (BPI) under an 

administrative protective order (APO) 

and BPI service list. Pursuant to section 

207.7(a) of the Commission’s rules, the 

Secretary will make BPI gathered in 

these reviews available to authorized 

applicants representing interested 

parties (as defined in 19 U.S.C. 1677(9)) 

who are parties to the reviews under the 

APO issued in the proceedings, 

provided that the application is made 

not later than 14 days after the 

publication of this notice in the Federal 

Register. A separate service list will be 

maintained by the Secretary for those 

parties authorized to receive BPI under 

the APO. 

Written submissions. Parties will have 

the opportunity to file two written 

submissions in these reviews. The first 

submission may contain any factual 

information pertinent to the 

determinations that the Commission is 

required to make pursuant to sections 

704(h) and 734(h) of the Act and 

arguments concerning the significance 

of this information, or information in 

the record of Sugar from Mexico, Inv. 

Nos. 701–TA–513 and 731–TA–1249 

(Preliminary) (‘‘the preliminary phase 

investigations’’) to these determinations. 

The Commission is particularly 

interested in receiving parties’ views 

concerning the following issues: 

• What information the Commission 

should use to assess whether the 

injurious effect of the imports of the 

subject merchandise is eliminated 

completely by the suspension 

agreements 

• The time period the Commission 

should evaluate in assessing whether 

the injurious effect of the imports of 

the subject merchandise is eliminated 

completely by the suspension 

agreements 

• The standard the Commission should 

use to assess whether the injurious 

effect of imports of the subject 

merchandise is ‘‘eliminated 

completely’’ 

• The use of the singular word ‘‘effect’’ 

in the statute and whether the 

Commission is permitted or required 

to assess any ‘‘effect’’ other than that 

resulting from pricing of the subject 

merchandise under the suspension 

agreements. 

• Whether the Commission’s analysis of 

‘‘injurious effect’’ incorporates any 

analysis of injurious effect of imports 

of the subject merchandise caused by 

the suspension agreement itself. 

Parties need not resubmit any 

information that is in the record of the 

preliminary phase investigations, as this 

information will be included in the 

record of these reviews. This first 

submission shall be filed no later than 

Tuesday, February 10, 2015. 

The second submission should 

respond to arguments and information 

submitted in the first submissions as 

well as other information in the record. 

These submissions may contain no more 

than 20 pages of textual material, 

double-spaced and single-sided, when 

printed out on paper measuring 8.5 x 11 

inches. They may also include an 

appendix which may contain responses 

to specific requests from Commissioners 

and staff. Aside from the material in the 

appendix, the second submission may 

not contain new factual information. 

This second submission shall be filed 

no later than Thursday, February 26, 

2015. 

If written submissions contain BPI, 

they must conform with the 

requirements of sections 201.6, 207.3, 

and 207.7 of the Commission’s rules. 

Please consult the Commission’s rules, 

as amended, 76 FR 61937 (Oct. 6, 2011) 

and the Commission’s Handbook on 

Filing Procedures, 76 FR 62092 (Oct. 6, 

2011), available on the Commission’s 

Web site at http://edis.usitc.gov. 

In accordance with sections 201.16(c) 

and 207.3 of the rules, each document 

filed by a party to the review must be 

served on all other parties to the review 

(as identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Opportunities for Oral Presentation: 

The Commission will convene a 

proceeding on Thursday, February 19, 

2015, at 9:30 a.m. at 500 E Street SW., 

Washington, DC to receive oral 

presentations from parties to the 

reviews. The Commission will provide 

further information about the nature of 

this proceeding to the parties at a later 

date. 

Authority: These reviews are being 

conducted under authority of title VII of the 

Tariff Act of 1930; this notice is published 

pursuant to section 207.12 of the 

Commission’s rules. 

Issued: January 21, 2015. 

By order of the Commission. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2015–01264 Filed 1–23–15; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[USITC SE–15–006] 

Government in the Sunshine Act 

Meeting Notice 

AGENCY HOLDING THE MEETING: United 

States International Trade Commission. 

TIME AND DATE: February 5, 2015 at 2 

p.m. 

PLACE: Room 101, 500 E Street SW., 

Washington, DC 20436, Telephone: 

(202) 205–2000. 

STATUS: Open to the public. 

MATTERS TO BE CONSIDERED: 1. Agendas 

for future meetings: none. 

2. Minutes. 

3. Ratification List. 

4. Vote in Inv. Nos. 701–TA–458 and 

731–TA–1154 (Review) (Certain Kitchen 

Appliance Shelving and Racks from 

China). The Commission is currently 

scheduled to complete and file its 

determinations and views of the 

Commission on February 24, 2015. 

5. Outstanding action jackets: none. 

In accordance with Commission 

policy, subject matter listed above, not 

disposed of at the scheduled meeting, 

may be carried over to the agenda of the 

following meeting. 

Issued: January 21, 2015. 

By order of the Commission. 

William R. Bishop, 

Supervisory Hearings and Information 

Officer. 

[FR Doc. 2015–01387 Filed 1–22–15; 11:15 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Euticals, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before March 27, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 


emcdonald on DSK67QTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices 3979 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: 

The Attorney General has delegated 

his authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, and 

dispensers of controlled substances 

(other than final orders in connection 

with suspension, denial, or revocation 

of registration) has been redelegated to 

the Deputy Assistant Administrator of 

the DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR pt. 0, 

subpt. R, App. 

In accordance with 21 CFR 

1301.33(a), this is notice that on May 29, 

2014, Euticals, Inc., 2460 W. Bennett 

Street, Springfield, Missouri 65807– 

1229, applied to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Controlled substance Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Oripavine (9330) ........................... II 

Tapentadol (9780) ........................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution and sale to its 

customers. 

In reference to Amphetamine (1100), 

the company plans to acquire the listed 

controlled substance in bulk from a 

domestic source in order to manufacture 

other controlled substances in bulk for 

distribution to its customers. 

Dated: January 9, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–01312 Filed 1–23–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Halo 

Pharmaceutical, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before March 27, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: 

The Attorney General has delegated 

his authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, and 

dispensers, of controlled substances 

(other than final orders in connection 

with suspension, denial, or revocation 

of registration) has been redelegated to 

the Deputy Assistant Administrator of 

the DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR pt. 0, 

subpt. R, App. 

In accordance with 21 CFR 

1301.33(a), this is notice that on July 21, 

2014, Halo Pharmaceutical, Inc., 30 

North Jefferson Road, Whippany, New 

Jersey 07981, applied to be registered as 

a bulk manufacturer of the following 

basic classes of controlled substances: 

Controlled substance Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

The company plans to manufacture 

Hydromorphone HCl for sale to other 

manufacturers and to manufacture other 

controlled substances for distribution to 

its customers. Dihydromorphine is an 

intermediate in the manufacture of 

Hydromorphone and is not for 

commercial distribution. 

Dated: January 9, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–01313 Filed 1–23–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before February 25, 2015. Such 

persons may also file a written request 

for a hearing on the application 

pursuant to 21 CFR 1301.43 on or before 

February 25, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of importers, 

of controlled substances (other than 

final orders in connection with 

suspension, denial, or revocation of 

registration) has been redelegated to the 

Deputy Assistant Administrator of the 

DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR pt. 0, 

subpt. R, App. 

In accordance with 21 CFR 

1301.34(a), this is notice that on June 

16, 2014, Fisher Clinical Services, Inc. 

7554 Schantz Road, Allentown, 

Pennsylvania 18106 applied to be 

registered as an importer of the 

following basic classes of controlled 

substances: 


emcdonald on DSK67QTVN1PROD with NOTICES